Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Anemia

Free Subscription Articles published in Am J Hematol Retrieve available abstracts of 159 articles: HTML format

Single Articles

October 2025
1. AL-SAMKARI H, Mayne TJ, Troutt M, Patle H, et al
   Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia.
   Am J Hematol. 2025;100:1722-1735.
   PubMed     Abstract available
   
   
   September 2025
2. COATES TD
   Early Detection of Diastolic Dysfunction in Sickle Cell Anemia: Can It Help the Patient and Let Us See the Elephant in the Room?
   Am J Hematol. 2025 Sep 24. doi: 10.1002/ajh.70073.
   PubMed    
   
   
   
3. ZAIMOKU Y, Yamazaki H, Kanaya M, Hiramoto N, et al
   Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia.
   Am J Hematol. 2025 Sep 5. doi: 10.1002/ajh.70054.
   PubMed     Abstract available
   
   
   
4. CHEVALIER K, Holub M, Palich R, Blanckaert K, et al
   Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study (MyCOLD Study).
   Am J Hematol. 2025;100:1557-1565.
   PubMed     Abstract available
   
   
   
5. ZADRO Y, Lusque A, Rey H, Cougoul P, et al
   Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones.
   Am J Hematol. 2025;100:1670-1674.
   PubMed     Abstract available
   
   
   August 2025
6. ANDERSON JR, Hollenhorst MA
   Double Bite Cells in Oxidative Hemolytic Anemia.
   Am J Hematol. 2025 Aug 13. doi: 10.1002/ajh.70035.
   PubMed     Abstract available
   
   
   July 2025
7. AMARU R, Prchal J, Carrasco M, Mancilla S, et al
   History of Thrombosis at High Altitude Associates With Increased Erythropoietin.
   Am J Hematol. 2025 Jul 30. doi: 10.1002/ajh.70025.
   PubMed     Abstract available
   
   
   
8. HUET S, Kamdem A, Beaufront V, Yakouben K, et al
   Reversal of Glomerular Hyperfiltration Following Hematopoietic Stem Cell Transplantation in Children With Sickle-Cell Anemia.
   Am J Hematol. 2025 Jul 16. doi: 10.1002/ajh.70004.
   PubMed    
   
   
   
9. BOULARES A, Bragazzi NL, Gonzales GF, Robach P, et al
   Addressing Anemia in High-Altitude Populations: Global Impact, Prevalence, Challenges, and Potential Solutions.
   Am J Hematol. 2025 Jul 2. doi: 10.1002/ajh.27761.
   PubMed     Abstract available
   
   
   
10. MORRIS CR, Hatabah D, Korman R, Gillespie S, et al
    Arginine Therapy for Pain in Sickle Cell Disease: A Phase-2 Randomized, Placebo-Controlled Trial.
    Am J Hematol. 2025;100:1119-1131.
    PubMed     Abstract available
    
    
    
11. WANG D, Sra M, Glaeser-Khan S, Wang DY, et al
    Cost-Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive-Age Women.
    Am J Hematol. 2025;100:1132-1140.
    PubMed     Abstract available
    
    
    June 2025
12. BREWIN J, Clark B, Smith F, Parkin N, et al
    Loss of Function SPTA1 Variants Causes Neonatal Liver Failure and Fetal Anemia.
    Am J Hematol. 2025 Jun 26. doi: 10.1002/ajh.27751.
    PubMed    
    
    
    
13. MAFFIOLI M, Mora B, Iurlo A, Elli EM, et al
    The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.
    Am J Hematol. 2025 Jun 6. doi: 10.1002/ajh.27734.
    PubMed    
    
    
    
14. RICCI E, Bagnasco F, Pierri F, Risitano A, et al
    Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology).
    Am J Hematol. 2025 Jun 6. doi: 10.1002/ajh.27724.
    PubMed     Abstract available
    
    
    May 2025
15. JACOBS JW, Raza S, Clark LM, Stephens LD, et al
    Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.
    Am J Hematol. 2025 May 20. doi: 10.1002/ajh.27721.
    PubMed     Abstract available
    
    
    
16. MEJIAS-FIGUEROA JA, Rodeghier M, DeBaun MR
    Impact of Switching From Race-Based to Race-Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia.
    Am J Hematol. 2025 May 12. doi: 10.1002/ajh.27704.
    PubMed    
    
    
    
17. BESHAI M, Alhomsi N, Warkentin TE
    Thrombocytopenia and Anemia After Cardiac Surgery.
    Am J Hematol. 2025 May 2. doi: 10.1002/ajh.27696.
    PubMed    
    
    
    
18. TRAETS MJM, Bos JF, van der Veen S, van Pelt L, et al
    Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.
    Am J Hematol. 2025;100:785-796.
    PubMed     Abstract available
    
    
    
19. MAGAGNOLI J, Knopf K, Hrushesky WJ, Carson KR, et al
    Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review.
    Am J Hematol. 2025;100:840-846.
    PubMed     Abstract available
    
    
    April 2025
20. ZAHR RS, Kang G, Zhang X, Rashkin SR, et al
    Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.
    Am J Hematol. 2025 Apr 5. doi: 10.1002/ajh.27678.
    PubMed     Abstract available
    
    
    March 2025
21. GANGAT N, Tefferi A
    Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.
    Am J Hematol. 2025 Mar 8. doi: 10.1002/ajh.27659.
    PubMed     Abstract available
    
    
    
22. JIANG D, Sampino EV, Rosenlind K, Campagna DR, et al
    Expanding the Phenotype of DNA Ligase 1 Deficiency: First Report of Macrocytic Sideroblastic Anemia.
    Am J Hematol. 2025 Mar 7. doi: 10.1002/ajh.27649.
    PubMed    
    
    
    February 2025
23. NAAMANSEN AB, Hansen DL, Petersen J, Glenthoj A, et al
    10-Year Risk of Gallstones in Congenital Red Blood Cell Disorder Patients: A Nationwide Cohort Study.
    Am J Hematol. 2025;100:229-235.
    PubMed     Abstract available
    
    
    January 2025
24. FATTIZZO B, Gurnari C, Giammarco S, Ricchiuti A, et al
    Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World.
    Am J Hematol. 2025 Jan 29. doi: 10.1002/ajh.27611.
    PubMed     Abstract available
    
    
    
25. WANG CY, Melgar-Bermudez E, Welch D, Dagbay KB, et al
    A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation.
    Am J Hematol. 2025 Jan 10. doi: 10.1002/ajh.27578.
    PubMed     Abstract available
    
    
    
26. KONTE K, Afzali-Hashemi L, Baas KPA, Schrantee A, et al
    Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease.
    Am J Hematol. 2025;100:78-84.
    PubMed     Abstract available
    
    
    
27. ROSATO BE, D'Onofrio V, Marra R, Nostroso A, et al
    RAS signaling pathway is essential in regulating PIEZO1-mediated hepatic iron overload in dehydrated hereditary stomatocytosis.
    Am J Hematol. 2025;100:52-65.
    PubMed     Abstract available
    
    
    
28. BOU-FAKHREDIN R, Cappellini MD, Taher AT, De Franceschi L, et al
    Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat.
    Am J Hematol. 2025;100:103-115.
    PubMed     Abstract available
    
    
    December 2024
29. LIN X, Yang C, Zhuang J, Li J, et al
    Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial.
    Am J Hematol. 2024 Dec 21. doi: 10.1002/ajh.27540.
    PubMed    
    
    
    
30. STUTE P, Akpan IJ, Breymann C, Murji A, et al
    Effect of Ferric Derisomaltose on Fatigue in Iron Deficiency Anemia Associated With Abnormal Uterine Bleeding.
    Am J Hematol. 2024 Dec 12. doi: 10.1002/ajh.27555.
    PubMed    
    
    
    
31. SISSOKO A, Cisse A, Duverdier C, Marin M, et al
    Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease.
    Am J Hematol. 2024;99:2267-2278.
    PubMed     Abstract available
    
    
    November 2024
32. RAMIREZ MJ, Pujol R, Minguillon J, Bogliolo M, et al
    Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.
    Am J Hematol. 2024 Nov 19. doi: 10.1002/ajh.27520.
    PubMed     Abstract available
    
    
    
33. MOSTAFA MA, Zand M, Taylor J, Kouides P, et al
    Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome.
    Am J Hematol. 2024;99:2241-2243.
    PubMed    
    
    
    
34. KULASEKARARAJ A, Lanza F, Arvanitakis A, Langemeijer S, et al
    Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:2108-2117.
    PubMed     Abstract available
    
    
    
35. VAN DOREN L, Brugnara C
    Self-pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas.
    Am J Hematol. 2024;99:2233-2235.
    PubMed    
    
    
    
36. CUMMINGS OW, Rahman S, Fletcher L, Scott AW, et al
    Advances in sickle cell retinopathy screening techniques, tests, and practices: A systematic review.
    Am J Hematol. 2024;99:2152-2163.
    PubMed     Abstract available
    
    
    
37. LAL A, Viprakasit V, Vichinsky E, Lai Y, et al
    Disease burden, management strategies, and unmet needs in alpha-thalassemia due to hemoglobin H disease.
    Am J Hematol. 2024;99:2164-2177.
    PubMed     Abstract available
    
    
    October 2024
38. BARCELLINI W, Pane F, Patriarca A, Murakhovskaya I, et al
    Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
    Am J Hematol. 2024 Oct 22. doi: 10.1002/ajh.27493.
    PubMed     Abstract available
    
    
    
39. CONNES P, Stauffer E, Liem RI, Nader E, et al
    Exercise and training in sickle cell disease: Safety, potential benefits, and recommendations.
    Am J Hematol. 2024;99:1988-2001.
    PubMed     Abstract available
    
    
    
40. ARNOLD SD, Bakshi N, Ross D, Smith C, et al
    Long-term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis.
    Am J Hematol. 2024;99:2037-2040.
    PubMed     Abstract available
    
    
    
41. CASELLA JF, Furstenau DK, Adams RJ, Brambilla DJ, et al
    Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.
    Am J Hematol. 2024;99:1906-1916.
    PubMed     Abstract available
    
    
    September 2024
42. BOUCHER AA, Dayton VJ, Pratt AR, Nassar NN, et al
    Three-generation female cohort with macrocytic anemia and iron overload.
    Am J Hematol. 2024 Sep 27. doi: 10.1002/ajh.27489.
    PubMed    
    
    
    
43. DELAFOY M, Dalle JH, Pondarre C, Andrieu GP, et al
    Assessing acute toxicity profiles of HLA-identical hematopoietic stem cell transplantation in pediatric patients with sickle cell anemia: A comprehensive analysis on behalf of the SFGM-TC.
    Am J Hematol. 2024 Sep 24. doi: 10.1002/ajh.27486.
    PubMed    
    
    
    
44. YOUNG DJ
    A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:1667-1669.
    PubMed    
    
    
    
45. SCHEINBERG P, Cle DV, Kim JS, Nur E, et al
    Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:1757-1767.
    PubMed     Abstract available
    
    
    
46. TORRES C, Galadanci N, Osborn J, Kanter J, et al
    Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease.
    Am J Hematol. 2024;99:1834-1836.
    PubMed    
    
    
    
47. ROTH A, He G, Tong H, Lin Z, et al
    Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
    Am J Hematol. 2024;99:1768-1777.
    PubMed     Abstract available
    
    
    August 2024
48. MEANS RT JR, Bi C, Wong ECC, Bare LA, et al
    Ferritin reference intervals in a population of working-age adults without anemia.
    Am J Hematol. 2024 Aug 5. doi: 10.1002/ajh.27444.
    PubMed    
    
    
    
49. ACHOUR A, Knijnenburg J, Koopmann T, Raz A, et al
    Moderate-severe beta-thalassemia intermedia phenotype caused by sextuplicated alpha-globin gene allele in two beta-thalassemia carriers.
    Am J Hematol. 2024;99:1655-1658.
    PubMed    
    
    
    
50. YU EA, Zacharias HU, Kelly S, Vichinsky E, et al
    Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent.
    Am J Hematol. 2024;99:1456-1458.
    PubMed    
    
    
    
51. BORTOLOTTI M, Trikha R, Salter S, Large J, et al
    Pregnancy in acquired bone marrow failure syndromes: Antenatal management and maternal and fetal outcomes.
    Am J Hematol. 2024;99:1647-1650.
    PubMed    
    
    
    
52. ITO S, Wang D, Purcell A, Chetlapalli K, et al
    Cost-effectiveness of sutimlimab in cold agglutinin disease.
    Am J Hematol. 2024;99:1475-1484.
    PubMed     Abstract available
    
    
    
53. DOVERN E, Aydin M, Hazenberg MD, Tang MW, et al
    Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study.
    Am J Hematol. 2024;99:1523-1531.
    PubMed     Abstract available
    
    
    
54. WEN S, Nisenbaum R, Weyand AC, Tang GH, et al
    High prevalence of iron deficiency and socioeconomic disparities in laboratory screening of non-pregnant females of reproductive age: A retrospective cohort study.
    Am J Hematol. 2024;99:1492-1499.
    PubMed     Abstract available
    
    
    
55. BORGEY M, Genty I, Habibi A, Arlet JB, et al
    High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long-term neonatal cohort study.
    Am J Hematol. 2024;99:1601-1605.
    PubMed    
    
    
    
56. VUONG C, Eckhardt CL, Heijboer H, Suijker MH, et al
    Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortality.
    Am J Hematol. 2024;99:1606-1609.
    PubMed    
    
    
    
57. SUN R, Srivastava A, Derebail VK, Han J, et al
    GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
    Am J Hematol. 2024;99:1610-1612.
    PubMed    
    
    
    
58. LUGTHART G, Verweij EJT, Harteveld CL, Tan RNGB, et al
    Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha-thalassemia.
    Am J Hematol. 2024;99:1613-1615.
    PubMed     Abstract available
    
    
    July 2024
59. VINCHI F
    New partners for Luspatercept in beta-thalassemia.
    Am J Hematol. 2024;99:1217-1219.
    PubMed    
    
    
    
60. KUO KHM, Grace RF, van Beers EJ, Barcellini W, et al
    Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.
    Am J Hematol. 2024;99:1415-1419.
    PubMed     Abstract available
    
    
    
61. GUERRA A, Hamilton N, Rivera A, Demsko P, et al
    Combination of a TGF-beta ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting beta-thalassemia.
    Am J Hematol. 2024;99:1300-1312.
    PubMed     Abstract available
    
    
    
62. PLACAIS M, Laparra A, Maria ATJ, Kramkimel N, et al
    Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.
    Am J Hematol. 2024;99:1427-1430.
    PubMed    
    
    
    
63. TANZI E, Di Modica SM, Bordini J, Olivari V, et al
    Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in beta-thalassemic mice.
    Am J Hematol. 2024;99:1313-1325.
    PubMed     Abstract available
    
    
    
64. WANG Z, Jiang B, Song L, Sun M, et al
    Patients with acquired pure red cell aplasia respond to PI3Kdelta inhibitor rapidly.
    Am J Hematol. 2024;99:1431-1433.
    PubMed    
    
    
    
65. CASTRO OL, De Franceschi L, Ganz T, Kanter J, et al
    Iron restriction in sickle cell disease: When less is more.
    Am J Hematol. 2024;99:1349-1359.
    PubMed     Abstract available
    
    
    
66. VAN DOREN L, Steinheiser M, Boykin K, Taylor KJ, et al
    Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions.
    Am J Hematol. 2024;99:1338-1348.
    PubMed     Abstract available
    
    
    June 2024
67. GANGAT N, Tefferi A
    Targeting anemia in myeloid neoplasms.
    Am J Hematol. 2024 Jun 5. doi: 10.1002/ajh.27408.
    PubMed     Abstract available
    
    
    
68. TUBMAN VN, Maysonet D, Estrada N, Halder T, et al
    Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine.
    Am J Hematol. 2024;99:1084-1094.
    PubMed     Abstract available
    
    
    
69. RONDELLI D
    Non-myeloablative allogeneic HSCT in adult patients with sickle cell disease: Multiple take-home points from the Saudi Arabia experience.
    Am J Hematol. 2024;99:1021-1022.
    PubMed    
    
    
    
70. MINNITI CP
    Let's get "real" in sickle cell disease: Real-world data and long-term patients' registries.
    Am J Hematol. 2024;99:1019-1020.
    PubMed    
    
    
    
71. DOVERN E, Aydin M, DeBaun MR, Alizade K, et al
    Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease-related organ complications: A systematic review and meta-analysis.
    Am J Hematol. 2024;99:1129-1141.
    PubMed     Abstract available
    
    
    
72. DAMLAJ M, Alahmari B, Alaskar A, Alhejazi A, et al
    Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients.
    Am J Hematol. 2024;99:1023-1030.
    PubMed     Abstract available
    
    
    
73. KWIATKOWSKI JL, Thompson AA, Tricta F, Temin NT, et al
    Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
    Am J Hematol. 2024;99:1031-1039.
    PubMed     Abstract available
    
    
    
74. JACOBS JW, Stephens LD, Chooljian DM, Sharma D, et al
    Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
    Am J Hematol. 2024;99:1016-1018.
    PubMed    
    
    
    
75. DE LIGT LA, Gaartman AE, Biemond BJ, Fijnvandraat K, et al
    Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target.
    Am J Hematol. 2024;99:1119-1128.
    PubMed     Abstract available
    
    
    May 2024
76. BROUSSE V, El Hoss S, Isnard P, Laurance S, et al
    Comparative histological analysis of spleens in pediatric patients with hemolytic anemias: Insights into the pathophysiological mechanisms of spleen destruction in sickle cell anemia.
    Am J Hematol. 2024 May 22. doi: 10.1002/ajh.27374.
    PubMed     Abstract available
    
    
    
77. MICHEL M, Sair M, Riviere E, Moulis G, et al
    Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study.
    Am J Hematol. 2024 May 14. doi: 10.1002/ajh.27361.
    PubMed    
    
    
    
78. NJOKU F, Pugh N, Brambilla D, Kroner B, et al
    Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
    Am J Hematol. 2024;99:900-909.
    PubMed     Abstract available
    
    
    
79. GRIFFIN M, Kelly R, Brindel I, Maafa L, et al
    Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:816-823.
    PubMed     Abstract available
    
    
    April 2024
80. MARRA R, Nostroso A, Rosato BE, Esposito FM, et al
    Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients.
    Am J Hematol. 2024 Apr 26. doi: 10.1002/ajh.27350.
    PubMed     Abstract available
    
    
    
81. YOSHIMI A, Noellke P, Stary J, Kallay K, et al
    Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia.
    Am J Hematol. 2024 Apr 15. doi: 10.1002/ajh.27334.
    PubMed    
    
    
    
82. JACKSON TA, Buscetta AJ, Ramirez HC, Bonham VL Jr, et al
    Leg ulcers are indicators of systemic dysfunction in individuals with sickle cell disease.
    Am J Hematol. 2024;99:767-769.
    PubMed     Abstract available
    
    
    
83. FATTIZZO B, Roth A, Broome CM, Khan U, et al
    COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
    Am J Hematol. 2024;99:789-791.
    PubMed     Abstract available
    
    
    
84. EAPEN M, Kou J, Andreansky M, Bhatia M, et al
    Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
    Am J Hematol. 2024;99:785-788.
    PubMed    
    
    
    
85. ITO S, Pandya A, Hauser RG, Krishnamurti L, et al
    Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
    Am J Hematol. 2024;99:570-576.
    PubMed     Abstract available
    
    
    
86. ALLALI S, Galacteros F, Oevermann L, Cannas G, et al
    Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.
    Am J Hematol. 2024;99:555-561.
    PubMed     Abstract available
    
    
    March 2024
87. GIARDINO S, Eikema DJ, Piepenbroek B, Algeri M, et al
    HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.
    Am J Hematol. 2024 Mar 18. doi: 10.1002/ajh.27293.
    PubMed     Abstract available
    
    
    
88. SHORT V, Allen R, Earley CJ, Bahrain H, et al
    A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
    Am J Hematol. 2024 Mar 13. doi: 10.1002/ajh.27290.
    PubMed     Abstract available
    
    
    
89. SICA M, Notaro R
    The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
    Am J Hematol. 2024;99:505-507.
    PubMed     Abstract available
    
    
    
90. MUSALLAM KM, Barella S, Origa R, Ferrero GB, et al
    'Phenoconversion' in adult patients with beta-thalassemia.
    Am J Hematol. 2024;99:490-493.
    PubMed     Abstract available
    
    
    
91. JACOBS JW, Booth GS, Woo JS, Adkins BD, et al
    How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria.
    Am J Hematol. 2024;99:484-485.
    PubMed     Abstract available
    
    
    
92. CORBACIOGLU S, Frangoul H, Locatelli F, Hobbs W, et al
    Defining curative endpoints for transfusion-dependent beta-thalassemia in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:422-429.
    PubMed     Abstract available
    
    
    
93. LOCATELLI F, Corbacioglu S, Hobbs W, Frangoul H, et al
    Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:430-438.
    PubMed     Abstract available
    
    
    February 2024
94. POWER-HAYS A, Tomlinson GA, Tshilolo L, Santos B, et al
    Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Am J Hematol. 2024 Feb 8. doi: 10.1002/ajh.27244.
    PubMed     Abstract available
    
    
    
95. ABDULLAHI SU, Sunusi S, Aminu H, Umar R, et al
    Transcranial doppler velocity in iron-deficient Nigerian children with sickle cell anemia.
    Am J Hematol. 2024 Feb 7. doi: 10.1002/ajh.27230.
    PubMed     Abstract available
    
    
    
96. TEFFERI A, Pardanani A, Gangat N
    Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Am J Hematol. 2024;99:300-308.
    PubMed     Abstract available
    
    
    
97. SOUISSI M, Daliphard S, Picard V, Lebigot E, et al
    Elevated MCHC reveals a Southeast Asian Ovalocytosis.
    Am J Hematol. 2024;99:331-332.
    PubMed    
    
    
    
98. CHEN M, Hankins JS, Zhang M, Ataga KI, et al
    Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
    Am J Hematol. 2024;99:E37-E41.
    PubMed     Abstract available
    
    
    
99. AFZALI-HASHEMI L, Dovern E, Baas KPA, Schrantee A, et al
    Cerebral hemodynamics and oxygenation in adult patients with sickle cell disease after stem cell transplantation.
    Am J Hematol. 2024;99:163-171.
    PubMed     Abstract available
    
    
    
100. GARBOWSKI MW, Ugidos M, Risueno A, Shetty JK, et al
     Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
     Am J Hematol. 2024;99:182-192.
     PubMed     Abstract available
     
     
     January 2024
101. SHAGIDOV D, Guttmann-Raviv N, Cunat S, Frech L, et al
     A newly identified ferritin L-subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia.
     Am J Hematol. 2024;99:12-20.
     PubMed     Abstract available
     
     
     
102. SEIDL E, Wilson D, Odame I, Kirby-Allen M, et al
     Lung function decline in children with sickle cell disease treated with hydroxyurea.
     Am J Hematol. 2024;99:E19-E21.
     PubMed    
     
     
     December 2023
103. PINTO VM, Romano N, Balocco M, Carrara P, et al
     Reduction of extramedullary erythropoiesis and amelioration of anemia in a beta-thalassemia patient treated with thalidomide.
     Am J Hematol. 2023 Dec 26. doi: 10.1002/ajh.27189.
     PubMed     Abstract available
     
     
     
104. SOULIE A, Kamdem A, Neumann F, Hau I, et al
     Clinical events in a long-term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea.
     Am J Hematol. 2023;98:E395-E398.
     PubMed    
     
     
     
105. HATEM A, Esperti S, Murciano N, Qiao M, et al
     Adverse effects of delta-9-tetrahydrocannabinol on sickle red blood cells.
     Am J Hematol. 2023;98:E383-E386.
     PubMed     Abstract available
     
     
     
106. BARAKAT A, Jasuja R, Tomlinson L, Wenzel Z, et al
     Effects of 2,3-DPG knockout on SCD phenotype in Townes SCD model mice.
     Am J Hematol. 2023;98:1838-1846.
     PubMed     Abstract available
     
     
     November 2023
107. KHO S, Siregar NC, Qotrunnada L, Fricot A, et al
     Retention of uninfected red blood cells causing congestive splenomegaly is the major mechanism of anemia in malaria.
     Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27152.
     PubMed     Abstract available
     
     
     
108. HONG HG, Gouveia MH, Ogwang MD, Kerchan P, et al
     Sickle cell allele HBB-rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa.
     Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27149.
     PubMed     Abstract available
     
     
     
109. KUTER DJ, Piatek C, Roth A, Siddiqui A, et al
     Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
     Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27144.
     PubMed     Abstract available
     
     
     
110. PINCEZ T, Lettre G
     Re-assessing the effect of fetal hemoglobin on stroke in the Cooperative Study of Sickle Cell Disease.
     Am J Hematol. 2023;98:E309-E311.
     PubMed    
     
     
     
111. THOMAS B, Visanica S, Poussing S, Gerard D, et al
     Is this really thalassemia?
     Am J Hematol. 2023;98:1814-1815.
     PubMed    
     
     
     
112. 
     Withdrawal: "Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost-effective." Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. La
     Am J Hematol. 2023;98:1819.
     PubMed     Abstract available
     
     
     
113. DI MAURO M, El Hoss S, Nardo-Marino A, Stuart-Smith S, et al
     Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea.
     Am J Hematol. 2023;98:E341-E344.
     PubMed     Abstract available
     
     
     October 2023
114. CASIMIR M, Colard M, Dussiot M, Roussel C, et al
     Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27117.
     PubMed     Abstract available
     
     
     
115. ARCHER NM, Gnangnon B, Mikdar M, Ciuculescu MF, et al
     F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease.
     Am J Hematol. 2023;98:1598-1605.
     PubMed     Abstract available
     
     
     
116. STEINBERG MH, Gladwin MT
     "Severity" in adult sickle cell disease.
     Am J Hematol. 2023;98:1508-1511.
     PubMed    
     
     
     
117. WALSH PS, Brousseau DC, Coleman KD
     Return visits after emergency department treatment for sickle cell pain crises.
     Am J Hematol. 2023;98:E266-E268.
     PubMed    
     
     
     September 2023
118. VAN DIJK MJ, van Oirschot BA, Harrison AN, Recktenwald SM, et al
     A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia.
     Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27088.
     PubMed     Abstract available
     
     
     
119. PORTER JB, Scrimgeour A, Martinez A, James L, et al
     SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
     Am J Hematol. 2023;98:1425-1435.
     PubMed     Abstract available
     
     
     
120. LIU H, Xia L, Weng J, Zhang F, et al
     Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
     Am J Hematol. 2023;98:1407-1414.
     PubMed     Abstract available
     
     
     
121. ELALFY MS, Hamdy M, Adly A, Ebeid FSE, et al
     Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
     Am J Hematol. 2023;98:1415-1424.
     PubMed     Abstract available
     
     
     
122. MUSALLAM KM, Lombard L, Kistler KD, Arregui M, et al
     Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps.
     Am J Hematol. 2023;98:1436-1451.
     PubMed     Abstract available
     
     
     
123. VON SIEBENTHAL HK, Moretti D, Zimmermann MB, Stoffel NU, et al
     Effect of dietary factors and time of day on iron absorption from oral iron supplements in iron deficient women.
     Am J Hematol. 2023;98:1356-1363.
     PubMed     Abstract available
     
     
     
124. NYANGASA S, Solomon D, Njiro B, Faisal A, et al
     The rate and pattern of fetal hemoglobin decline adjusted to sickle cell status of newborns in Dar es Salaam, Tanzania: A prospective cohort study.
     Am J Hematol. 2023;98:E241-E243.
     PubMed     Abstract available
     
     
     
125. PIRAN S, Alhomsi N, Warkentin TE
     Recurrent severe thrombocytopenia in critical illness complicated by hemolysis.
     Am J Hematol. 2023;98:1490-1496.
     PubMed    
     
     
     August 2023
126. NAIR M, Choudhury SS, Rani A, Solomi C 5th, et al
     The complex relationship between iron status and anemia in pregnant and postpartum women in India: Analysis of two Indian study cohorts of uncomplicated pregnancies.
     Am J Hematol. 2023 Aug 31. doi: 10.1002/ajh.27059.
     PubMed     Abstract available
     
     
     
127. AGARWAL S, Stanek JR, Vesely SK, Creary SE, et al
     Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.
     Am J Hematol. 2023 Aug 8. doi: 10.1002/ajh.27045.
     PubMed     Abstract available
     
     
     
128. PATNAIK MM, Tefferi A
     Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
     Am J Hematol. 2023;98:1171-1175.
     PubMed    
     
     
     
129. SACHDEV V, Limerick E, Nguyen ML, Li W, et al
     Cardiac effects 2 years after successful non-myeloablative human leukocyte antigen-matched related donor hematopoietic cell transplants in sickle cell disease.
     Am J Hematol. 2023;98:E219-E221.
     PubMed    
     
     
     
130. ROTH A, Barcellini W, D'Sa S, Miyakawa Y, et al
     Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
     Am J Hematol. 2023;98:1246-1253.
     PubMed     Abstract available
     
     
     
131. LANINO L, Restuccia F, Perego A, Ubezio M, et al
     Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
     Am J Hematol. 2023;98:E204-E208.
     PubMed    
     
     
     
132. GROS M, Pondarre C, Arnaud C, Kamdem A, et al
     Lung function after matched-related donor allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
     Am J Hematol. 2023;98:E212-E215.
     PubMed    
     
     
     
133. LIU A, Kremyanskaya M, Mehrazin R, Si Q, et al
     Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis.
     Am J Hematol. 2023 Aug 1. doi: 10.1002/ajh.27047.
     PubMed    
     
     
     July 2023
134. ZHANG L, Zhao J, Li R, Pan H, et al
     Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.
     Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27028.
     PubMed    
     
     
     
135. MCGLOTHLIN J, Abeykoon J, Al-Hattab E, Ashrani AA, et al
     Bortezomib and daratumumab in refractory autoimmune hemolytic anemia.
     Am J Hematol. 2023 Jul 7. doi: 10.1002/ajh.27025.
     PubMed    
     
     
     
136. POWERS JM, Auerbach M
     When taking iron, a glass of orange juice a day keeps anemia away.
     Am J Hematol. 2023 Jul 4. doi: 10.1002/ajh.27017.
     PubMed    
     
     
     
137. RIBEIL JA, Pollock G, Frangoul H, Steinberg MH, et al
     An integrated therapeutic approach to sickle cell disease management beyond infancy.
     Am J Hematol. 2023;98:1087-1096.
     PubMed     Abstract available
     
     
     
138. ALLALI S, Elie J, Mayrand L, de Montalembert M, et al
     Sputum IL-6 level as a potential predictor of acute chest syndrome during vaso-occlusive crisis in children with sickle cell disease: Exploratory prospective prognostic accuracy study.
     Am J Hematol. 2023;98:E175-E178.
     PubMed    
     
     
     
139. D'ALESSANDRO A, Nouraie SM, Zhang Y, Cendali F, et al
     In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
     Am J Hematol. 2023;98:1017-1028.
     PubMed     Abstract available
     
     
     June 2023
140. URIO F, Nkya S, Mgaya J, Rooks H, et al
     Gender effect on production and enrichment of F cell numbers in sickle cell disease patients in Tanzania.
     Am J Hematol. 2023;98:E139-E141.
     PubMed    
     
     
     
141. PINTO VM, Russo R, Quintino S, Rosato BE, et al
     Coinheritance of PIEZO1 variants and multi-locus red blood cell defects account for the symptomatic phenotype in beta-thalassemia carriers.
     Am J Hematol. 2023;98:E130-E133.
     PubMed     Abstract available
     
     
     
142. BORDONI V, Casale M, Pinto VM, Carsetti R, et al
     Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients.
     Am J Hematol. 2023;98:E145-E147.
     PubMed    
     
     
     
143. CHEN PH, Gorshein E, Tormey C, Siddon AJ, et al
     "Double-hit" ineffective erythropoiesis-concurrent beta-thalassemia with alpha-gene triplication and myelodysplastic syndrome with SF3B1 mutation.
     Am J Hematol. 2023;98:984-988.
     PubMed    
     
     
     May 2023
144. PEFFAULT DE LATOUR R, Risitano AM
     Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond.
     Am J Hematol. 2023;98 Suppl 4:S3-S4.
     PubMed    
     
     
     
145. KULASEKARARAJ AG, Lazana I
     Paroxysmal nocturnal hemoglobinuria: Where are we going.
     Am J Hematol. 2023;98 Suppl 4:S33-S43.
     PubMed     Abstract available
     
     
     
146. DUVAL A, Fremeaux-Bacchi V
     Complement biology for hematologists.
     Am J Hematol. 2023;98 Suppl 4:S5-S19.
     PubMed     Abstract available
     
     
     
147. LEON J, LeStang MB, Sberro-Soussan R, Servais A, et al
     Complement-driven hemolytic uremic syndrome.
     Am J Hematol. 2023;98 Suppl 4:S44-S56.
     PubMed     Abstract available
     
     
     
148. PANSE J
     Paroxysmal nocturnal hemoglobinuria: Where we stand.
     Am J Hematol. 2023;98 Suppl 4:S20-S32.
     PubMed     Abstract available
     
     
     
149. DIAMANTOPOULOS PT, Solomou E, Symeonidis A, Pappa V, et al
     The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
     Am J Hematol. 2023;98:E119-E122.
     PubMed    
     
     
     
150. POURDIEU C, El Hoss S, Le Roux E, Pages J, et al
     Relevance of Howell-Jolly body counts for measuring spleen function in sickle cell disease.
     Am J Hematol. 2023;98:E110-E112.
     PubMed    
     
     
     
151. GAARTMAN AE, van Tuijn CFJ, Nur E, Vogt L, et al
     The association between renal function decline and disease severity in sickle cell disease.
     Am J Hematol. 2023;98:E95-E97.
     PubMed    
     
     
     April 2023
152. TEFFERI A, Vannucchi AM
     JAK2 inhibitor treatment of anemia in myelofibrosis.
     Am J Hematol. 2023 Apr 21. doi: 10.1002/ajh.26934.
     PubMed    
     
     
     
153. AGGARWAL N, Manley AL, Shalhoub R, Durrani J, et al
     Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
     Am J Hematol. 2023 Apr 6. doi: 10.1002/ajh.26924.
     PubMed     Abstract available
     
     
     
154. ONI MO, Archer NM
     Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
     Am J Hematol. 2023;98:564-565.
     PubMed    
     
     
     
155. REES CA, Brousseau DC, Ahmad FA, Bennett J, et al
     Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
     Am J Hematol. 2023;98:620-627.
     PubMed     Abstract available
     
     
     
156. REDJOUL R, Beckerich F, de Luna G, Leclerc M, et al
     ABO blood barrier to engraftment after allogeneic stem cell transplantation in sickle cell disease: A case-story with two successive HLA-matched sibling donors.
     Am J Hematol. 2023;98:692-696.
     PubMed    
     
     
     March 2023
157. RISINGER M, Kim PS, Rodriguez RX, Narvaez Rivas M, et al
     Hemolytic anemia and macrothrombocytopenia: a lipid problem?
     Am J Hematol. 2023 Mar 28. doi: 10.1002/ajh.26916.
     PubMed    
     
     
     
158. RAI P, Okhomina VI, Kang G, Martinez HR, et al
     Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
     Am J Hematol. 2023 Mar 8. doi: 10.1002/ajh.26911.
     PubMed     Abstract available
     
     
     
159. LANSER L, Plaikner M, Schroll A, Burkert FR, et al
     Tissue iron distribution in patients with anemia of inflammation: results of a pilot study.
     Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26909.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge.